Department of Cardiology, West China Hospital, Sichuan University, Chengdu 610041, China.
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Oxid Med Cell Longev. 2021 Jan 29;2021:8854790. doi: 10.1155/2021/8854790. eCollection 2021.
Currently, traditional cancer therapy still falls far short of expectations. However, a variety of invasive cancers that are resistant to chemotherapy (such as platinum drugs, one of the most applied antineoplastics in clinic) and targeted agents are susceptible to ferroptosis. Ferroptosis is a form of cell death that is driven by cell metabolism and iron-dependent lipid peroxidation. Ferroptosis inducers can eliminate the drug resistance of tumor cells in the mesenchymal state, effectively inhibit the drug resistance of acquired tumor cells, and optimize cancer efficacy. Research based on the epigenetic mechanism of ferroptosis is still in the stage of screening and verifying the regulatory effect, and there is no complete regulatory mechanism network. In this review, we expound on the epigenetic regulation and nonepigenetic mechanisms of ferroptosis and review the epigenetic-based mechanisms of tumor therapy potential and emerging nonepigenetic-based therapies (nanotherapeutics).
目前，传统癌症疗法仍远未达到预期效果。然而，多种对化疗（如铂类药物，是临床上应用最广泛的抗肿瘤药物之一）和靶向药物有耐药性的侵袭性癌症对铁死亡敏感。铁死亡是一种由细胞代谢和铁依赖性脂质过氧化驱动的细胞死亡形式。铁死亡诱导剂可以消除间充质状态下肿瘤细胞的耐药性，有效抑制获得性肿瘤细胞的耐药性，优化癌症疗效。基于铁死亡的表观遗传机制的研究仍处于筛选和验证调控作用的阶段，尚未形成完整的调控机制网络。本文阐述了铁死亡的表观遗传调控和非表观遗传机制，并综述了基于表观遗传的肿瘤治疗潜力和新兴的非基于表观遗传的治疗方法（纳米治疗）。
